Despite Data Concerns, Panel Recommends First-In-Class Toe Implant
This article was originally published in The Gray Sheet
Cartiva, a toe implant to treat osteoarthritis, received a strong recommendation from a panel of FDA experts despite suggestions that the device had not fully proven itself.
You may also be interested in...
An FDA advisory panel recommended approval of Link Orthopedics' STAR ankle replacement system April 24 despite FDA reviewers' conclusion that results of the firm's pivotal trial are unclear
The program bringing Operation Warp Speed-like treatment to rare disease product development could expand if successful, but will require more employees and thus funding commitments from Congress and industry, CBER Director Peter Marks said.
Academics assert more should be done to restore pre-pandemic site-inspection activity levels, especially abroad, following analysis of 10 years of data on US FDA inspection trends, costs and resources published in Health Affairs.